Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000418627 | SCV000513069 | likely benign | not provided | 2020-08-07 | criteria provided, single submitter | clinical testing | Has not been previously published as pathogenic or benign to our knowledge; In silico analysis supports that this missense variant does not alter protein structure/function |
Blueprint Genetics | RCV000418627 | SCV000928107 | uncertain significance | not provided | 2018-12-09 | criteria provided, single submitter | clinical testing | |
Invitae | RCV000812023 | SCV000952321 | uncertain significance | Myofibrillar myopathy 5; Distal myopathy with posterior leg and anterior hand involvement; Hypertrophic cardiomyopathy 26; Dilated Cardiomyopathy, Dominant | 2023-12-01 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with glutamine, which is neutral and polar, at codon 1159 of the FLNC protein (p.Arg1159Gln). This variant is present in population databases (rs141199483, gnomAD 0.01%), and has an allele count higher than expected for a pathogenic variant. This variant has not been reported in the literature in individuals affected with FLNC-related conditions. ClinVar contains an entry for this variant (Variation ID: 377889). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) has been performed at Invitae for this missense variant, however the output from this modeling did not meet the statistical confidence thresholds required to predict the impact of this variant on FLNC protein function. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Revvity Omics, |
RCV000418627 | SCV003831411 | uncertain significance | not provided | 2020-03-27 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003168624 | SCV003859308 | uncertain significance | Cardiovascular phenotype | 2022-11-17 | criteria provided, single submitter | clinical testing | The p.R1159Q variant (also known as c.3476G>A), located in coding exon 21 of the FLNC gene, results from a G to A substitution at nucleotide position 3476. The arginine at codon 1159 is replaced by glutamine, an amino acid with highly similar properties. This amino acid position is conserved. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |